Genelux Corporation Common Stock (NASDAQ:GNLX) — Market Cap & Net Worth
Market Cap & Net Worth: Genelux Corporation Common Stock (GNLX)
Genelux Corporation Common Stock (NASDAQ:GNLX) has a market capitalization of $117.61 Million ($117.61 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18577 globally and #4108 in its home market, demonstrating a 8.73% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Genelux Corporation Common Stock's stock price $2.74 by its total outstanding shares 44718438 (44.72 Million). Analyse GNLX operating cash flow to see how efficiently the company converts income to cash.
Genelux Corporation Common Stock Market Cap History: 2023 to 2026
Genelux Corporation Common Stock's market capitalization history from 2023 to 2026. Data shows change from $626.51 Million to $122.53 Million (-21.95% CAGR).
Index Memberships
Genelux Corporation Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #523 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1808 of 3165 |
Weight: Genelux Corporation Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Genelux Corporation Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Genelux Corporation Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
13191.94x
Genelux Corporation Common Stock's market cap is 13191.94 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $626.51 Million | $170.00K | -$28.30 Million | 3685.33x | N/A |
| 2024 | $105.54 Million | $8.00K | -$29.87 Million | 13191.94x | N/A |
Competitor Companies of GNLX by Market Capitalization
Companies near Genelux Corporation Common Stock in the global market cap rankings as of May 4, 2026.
Key companies related to Genelux Corporation Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Genelux Corporation Common Stock Historical Marketcap From 2023 to 2026
Between 2023 and today, Genelux Corporation Common Stock's market cap moved from $626.51 Million to $ 122.53 Million, with a yearly change of -21.95%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $122.53 Million | -37.16% |
| 2025 | $194.97 Million | +84.75% |
| 2024 | $105.54 Million | -83.15% |
| 2023 | $626.51 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Genelux Corporation Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $117.61 Million USD |
| MoneyControl | $117.61 Million USD |
| MarketWatch | $117.61 Million USD |
| marketcap.company | $117.61 Million USD |
| Reuters | $117.61 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Genelux Corporation Common Stock
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or s… Read more